- Home
- ALLR vs LIPO Comparison
ALLR vs LIPO Comparison
Compare ALLR & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- LIPO
- Stock Information
- Founded
- ALLR 2004
- LIPO 2005
- Country
- ALLR United States
- LIPO United States
- Employees
- ALLR N/A
- LIPO N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- LIPO Health Care
- Exchange
- ALLR Nasdaq
- LIPO Nasdaq
- Market Cap
- ALLR 4.7M
- LIPO 3.8M
- IPO Year
- ALLR N/A
- LIPO 2022
- Fundamental
- Price
- ALLR $1.05
- LIPO $2.85
- Analyst Decision
- ALLR
- LIPO Strong Buy
- Analyst Count
- ALLR 0
- LIPO 1
- Target Price
- ALLR N/A
- LIPO $16.00
- AVG Volume (30 Days)
- ALLR 2.6M
- LIPO 91.5K
- Earning Date
- ALLR 03-07-2025
- LIPO 02-25-2025
- Dividend Yield
- ALLR N/A
- LIPO N/A
- EPS Growth
- ALLR N/A
- LIPO N/A
- EPS
- ALLR N/A
- LIPO N/A
- Revenue
- ALLR N/A
- LIPO $483,533.00
- Revenue This Year
- ALLR N/A
- LIPO N/A
- Revenue Next Year
- ALLR N/A
- LIPO N/A
- P/E Ratio
- ALLR N/A
- LIPO N/A
- Revenue Growth
- ALLR N/A
- LIPO 0.78
- 52 Week Low
- ALLR $0.90
- LIPO $2.21
- 52 Week High
- ALLR $288.00
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- ALLR 47.15
- LIPO 45.72
- Support Level
- ALLR $0.96
- LIPO $2.78
- Resistance Level
- ALLR $1.72
- LIPO $3.17
- Average True Range (ATR)
- ALLR 0.17
- LIPO 0.29
- MACD
- ALLR 0.01
- LIPO -0.04
- Stochastic Oscillator
- ALLR 13.99
- LIPO 7.61
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.